Análise de segurança de estudos randomizados mostrou que o aducanumabe (medicamento para Alzheimer) causou edema cerebral em 35% dos pacientes e sintomas associados (cefaleia, confusão, tontura e náusea) em 26%.

Amyloid-Related Imaging Abnormalities in 2 Phase 3 Studies Evaluating Aducanumab in Patients With Early Alzheimer Disease – JAMA Neurology

Comentário: Biogen Alzheimer’s drug shows brain swelling in 35% of patients – MedicalXpress

Comentário no Twitter

Amyloid-related imaging abnormalities occurred in ~ 40% of participants in the phase 3 studies of aducanumab. Approximately one-quarter of patients with amyloid-related imaging abnormalities experience symptoms https://t.co/TnUPXT686l

— JAMA Neurology (@JAMANeuro) November 22, 2021